Previous 10 | Next 10 |
Allena Pharmaceuticals (NASDAQ: ALNA ): Q4 GAAP EPS of -$0.47 beats by $0.06 . More news on: Allena Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
-- Streamlined URIROX-2 Design Potentially Reduces Target Length and Cost of Trial -- -- Regulatory Engagement on Registrational Path for Reloxaliase in High-Risk Enteric Hyperoxaluria (EH) Patients with Chronic Kidney Disease (CKD) Expected in 2Q 2020 -- -- Investigational New D...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “This morning, ALNA announced proposed changes to URIROX-2, including reduction of overall EH patients (200 vs. 400) and adding an interi...
NEWTON, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, t...
AIM ImmunoTech (NYSEMKT: AIM ) +20% on discussing the potential role of Ampligen for use against the Wuhan 2019 Novel Coronavirus. More news on: AIM ImmunoTech Inc., TransEnterix, Inc., Shopify Inc., Stocks on the move, , Read more ...
Thinly traded nano cap Allena Pharmaceuticals (NASDAQ: ALNA ) is up 11% premarket on average volume on the heels of its announcement that the FDA has signed off, at least in principle, on a streamlined design for its second Phase 3 study evaluating reloxaliase for the potential...
-- Reducing Target Enrollment to 200 Subjects -- -- Conducting Earlier Interim Analysis, Expected in Q3 2021 -- -- Company to Host Conference Call at 8:30 a.m. ET Today -- NEWTON, Mass., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a lat...
– Prioritizing Development of Reloxaliase for Patients with Enteric Hyperoxaluria (EH) – – Plan to Re-Engage with U.S. Food and Drug Administration (FDA) to Evaluate Opportunities to Streamline URIROX-2, Second Pivotal Phase 3 Trial of Reloxaliase in EH&...
NEWTON, Mass., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, t...
News, Short Squeeze, Breakout and More Instantly...
Allena Pharmaceuticals Inc. Company Name:
ALNA Stock Symbol:
NASDAQ Market:
Allena Pharmaceuticals Inc. Website:
Buying Penny Stocks on July 29th? Here’s What You Need to Know If you’re looking for the best penny stocks to buy right now, there are hundreds of options to choose from. As a result, it all comes down to finding the best penny stocks that fit your trading strateg...
NEWTON, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), a biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme the...
NEWTON, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorde...